Trial Profile

Phase IIb, 12-week, five-arm, global, double-blind, placebo-controlled study of modified-release dipyridamole/prednisolone in patients with moderate to severe rheumatoid arthritis: SYNERGY.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dipyridamole/prednisolone (Primary) ; Dipyridamole; Prednisolone; Prednisone
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms SYNERGY
Sponsors Zalicus

13 Sep 2012 Primary endpoint 'significant difference between dipyridamole and placebo in disease-activity-score' has been met, according to a Zalicus media release.
13 Sep 2012 Secondary endpoint `significant difference between dipyridamole/prednisolone and prednisolone in disease activity score' not met, according to a Zalicus media release.
10 Sep 2012 Status of parent trial changed from active, no longer recruiting to completed, according to ClinicalTrials.gov (NCT01369745).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com